HOUSTON–(BUSINESS WIRE)–Tvardi Therapeutics, Inc. (“Tvardi”), a private clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that management will participate in one-on-one meetings with investors at the Morgan Stanley Access day for private companies to biotechnologies. The conference is being held in virtual format on Tuesday, May 3, 2022.
About Tvardi Therapeutics
Tvardi is a private, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of numerous signaling pathways essential for cancer cell survival and immune evasion. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is currently being studied in a single-agent, multicenter Phase 1 clinical trial in patients with advanced solid tumors. To date, TTI-101 has been well tolerated and has demonstrated durable multiple objective radiographic responses in patients treated with TTI. -101 monotherapy. To learn more, please visit https://tvarditherapeutics.com/